RAD 140 and TRT have never been measured in combination: no study has administered RAD140, a selective androgen receptor modulator (SARM) developed in oncology, with testosterone replacement therapy (TRT), testosterone prescribed to replace a low level. The only human trial, in women with breast cancer, recorded rises in liver enzymes, a risk that added testosterone does not cover.
Beyond that trial the published record on the combination is one case report, a single patient in whom products containing RAD-140 suppressed endogenous testosterone production until they were stopped. Outside the published trials, accounts of RAD 140 and libido describe that suppression as bringing low libido, low energy and mood swings where no base is held, and a testosterone base as replacing the lost production.
Two features of the compound frame the combination. RAD140 acts at the same site as testosterone rather than through a separate pathway, both binding the androgen receptor, a protein inside cells that responds to androgens; and the compound has been tested in humans only in a phase 1 trial (the earliest stage of clinical testing) in postmenopausal women with breast cancer, a population with no testicular output to suppress.
This dose-escalation study with a 3 + 3 design and PK expansion cohort enrolled postmenopausal women with ER+/HER2- metastatic breast cancer (mBC).
Nothing in the trial record describes the compound combined with a replacement dose of testosterone, and the RAD 140 science behind that record is a development history in oncology, not in hormone replacement.
Within those limits, this article sets out what the trial, the published case report and a review of hormone recovery hold on the combination, together with what is described outside the published studies; how either compound is administered, and the basics of RAD140 on its own, stay outside it.
What is a test base?
In descriptions beyond the trials, a test base is testosterone administered alongside a suppressive compound such as RAD 140, so that circulating testosterone is maintained while endogenous production falls; that fall is suppression, the decline in endogenous hormone output under an exogenous androgen, and RAD140 testosterone suppression of this kind is the reason these descriptions give for maintaining such a base.
Such a base has also been widely described, in those accounts, as already supplied by TRT at a prescribed replacement level, which is why the question of a base is put differently where testosterone is already prescribed (whether anything need change) than where it is not (what should be added). Other agents are sometimes described as a base too, among them a selective oestrogen receptor modulator (SERM), a drug whose action at the oestrogen receptor differs by tissue, and dehydroepiandrosterone (DHEA), an adrenal precursor steroid; the term itself belongs to these descriptions rather than to the medical literature, which recognises no such category.
What the RAD140 trial recorded on hormones
For a question about a testosterone base, the only human RAD 140 study has one defining feature: it enrolled nobody with testicular output. Its 22 participants were postmenopausal women with heavily pretreated metastatic breast cancer, 21 of them with androgen receptor-positive tumours, and it was built to find a tolerable dose in that disease, as a 3 + 3 dose escalation with an attached pharmacokinetic expansion cohort (small groups stepped up through rising doses until toxicity appears) at 50 mg (n = 6), 100 mg (n = 13) and 150 mg (n = 3), orally once daily, not to measure any hormonal axis.
The dose and the interval came out of that design. Toxicity appeared at the top level, so the maximum tolerated dose (the highest carried without unacceptable toxicity) was 100 mg a day, and the once-daily interval rested on the RAD 140 half life, an elimination half-life, the time a blood concentration takes to halve, of 44.7 hours.
On the endocrine side the trial read two surrogates of receptor engagement, and in women without testes both moved as a working androgen would: sex hormone-binding globulin (SHBG, the blood protein that binds testosterone) fell in 18 of 18 patients measured, and prostate-specific antigen (PSA), whose production rises on androgen receptor activation, rose. The two readings agreed with each other and with paired tumour biopsies taken before and during treatment, which is why the investigators treated receptor occupancy as demonstrated rather than inferred.
SHBG decreased in 18 per 18 patients, and PSA increased in 16 per 20 patients.
The risk that added testosterone does not cover is hepatic, since signs of RAD 140 liver toxicity dominated the trial’s safety record.
Does RAD140 shrink the prostate, and does that matter on TRT?
RAD140 has not been shown to shrink prostate tissue, and nothing in its only human trial points to such an effect: PSA rose in 16 of 20 patients in whom it was measured, and the authors read the rise as evidence of receptor engagement rather than of any action on the gland itself.
The patients were postmenopausal women, so prostate tissue was neither present nor measured and the PSA signal stands only as a pharmacodynamic marker. For TRT the limitation is specific: a rise in women cannot be carried over to men whose prostate tissue is already exposed to replacement testosterone, since the published record holds no readings from such men given RAD140, though the direction of the marker runs against the idea of a compound that lowers androgenic activity in the gland.
Hormone shutdown in a case report of products containing RAD140
Analytical chemistry, not the clinical course, is what makes the case report bear on a question about testosterone. The patient was a 40-year-old man with six months of exposure to three commercial supplements behind him when he presented with bilateral gynaecomastia (growth of glandular breast tissue in a male) and biochemical hypogonadotropic hypogonadism (low sex hormones that follow a reduced pituitary signal to the testes); in vitro analysis of the products detected RAD-140 alongside cardarine (a metabolic agent) and MK-677, a secretagogue that raises growth hormone, and the table below gives the whole inventory.
What the case report’s supplements contained
Substance
What it is
How the analysis reported it
RAD-140
Selective androgen receptor modulator
Detected; named as a banned performance-enhancing drug
MK-677
Growth hormone secretagogue
Detected; named as a banned performance-enhancing drug
Cardarine
Metabolic agent
Detected; named as a banned performance-enhancing drug
Testosterone
Androgen
Undisclosed; found in all 3 supplements
Oestradiol
Oestrogen
Undisclosed; found in all 3 supplements
Growth hormone
Pituitary hormone
Undisclosed; found in all 3 supplements
Unidentified compound
Not identified
Coeluted close to the testosterone peak on liquid chromatography mass spectrometry
The declared contents were not the whole of what the products held. All three contained undisclosed testosterone, oestradiol and growth hormone, and steroid analysis by liquid chromatography mass spectrometry also detected an unidentified compound coeluting close to the testosterone peak. That coeluting peak is the detail that bears on this article: a substance that cannot be resolved from testosterone on a chromatogram would be indistinguishable from prescribed testosterone as well, and the analysis could put no quantity on either.
Cessation of these supplements led to full resolution of symptoms including normalization of hypogonadotropic hypogonadism.
Once the products were withdrawn, every symptom resolved and the hypogonadotropic hypogonadism normalised. What the report records is reversibility, not a deliberate combination: the testosterone was undeclared, its amount unknown, several active compounds were present at once, and the whole observation rests on one patient (n = 1).
Does RAD140 with testosterone affect fertility?
RAD140 combined with testosterone is generally held to suppress male fertility, because each agent on its own is understood to lower the pituitary hormones that drive sperm production: exogenous testosterone reduces luteinising hormone and follicle-stimulating hormone, a fall that lowers intratesticular testosterone concentrations and can reduce or halt spermatogenesis, and SARMs suppress the same two hormones in a dose-dependent way, so the combination is expected to add to that suppression rather than offset it.
Once that androgen exposure ends, recovery of spermatogenesis is generally described as possible but slow, and as variable between individuals; for RAD140 itself, data on fertility in humans remain very limited, and none of the studies among this article’s sources measured semen parameters.
Why do people add RAD140 to TRT or a testosterone base?
Pairing RAD 140 and TRT, or a testosterone base, is described, outside the trial record, as resting most commonly on suppression, with the base said to replace the endogenous production the compound lowers, and the accounts that describe a RAD 140 and testosterone stack give the reasons below, from a settled argument to a question asked with no reason at all:
Suppression: the compound is said to suppress endogenous testosterone production and the base to replace what is lost before the decline produces symptoms, an argument put in a settled form, that a highly suppressive compound requires testosterone held alongside it.
A modest step for men already receiving prescribed testosterone: because their endogenous production is already replaced, the addition is presented as a modest step rather than full exposure to injectable anabolic-androgenic steroids, and the question becomes whether the compound can simply be placed on top of an existing regimen.
Lean body mass: RAD140 has also been described as adding more to lean body mass, relative to its adverse effects, than a larger amount of testosterone would add, a claim often repeated and nowhere measured.
No reason at all: the question is also put with no reason attached, asking whether RAD140 with testosterone is workable on TRT, or with a base, at any amount.
Combinations of more than two compounds, to which the same reasoning extends.
The evidence behind a RAD 140 stack covers less of such arrangements than those accounts assume.
RAD140 as a replacement for TRT in discussions
Beyond the trial data, RAD140 is sometimes described as a substitute for testosterone replacement therapy, and the claim meets an immediate objection, since a compound that suppresses endogenous testosterone cannot stand in for testosterone, and on that ground the substitution is sometimes described as a failure.
Variants of the substitution claim stand around the edges of that position in the same accounts, and the claims described run as follows:
RAD140 as a compound designed to replace testosterone replacement therapy
RAD140 as at least a possible alternative to it
RAD140 combined with oestrogen as behaving like replacement therapy
a small amount of RAD140 held indefinitely as possibly matching testosterone, put as a further question
All of these variants remain claims in those accounts rather than findings of the research record.
Does RAD140 on TRT give more than testosterone alone or a higher test dose?
Accounts outside the published studies describe RAD140 added to testosterone replacement therapy as contributing less than a higher dose of testosterone, most of them holding that more testosterone would produce an equal or greater effect with fewer unknowns, and the comparison is often put as a direct question: why the compound rather than testosterone, and why not raise the testosterone dose instead of introducing a second agent.
RAD140 added to prescribed testosterone has also been described as producing an effect that testosterone alone had not produced, a less frequent and occasionally emphatic account that most often names a reduction in fat mass or an increase in muscle strength, while elsewhere any such change is credited wholly to the prescribed testosterone and not at all to the compound, the same comparison made from the other end.
In those accounts each agent can at least be compared directly with placebo within its own evidence, and set out that way RAD 140 vs testosterone becomes a comparison of the underlying suppression and marker data.
Is a test base needed with RAD140?
A test base is most often held, among the effects described outside the trials, to be needed with RAD140 because the compound is highly suppressive, while a smaller set of accounts holds that it is not necessary; the disagreement comes back as one of the questions put most often, and in almost identical words, whether RAD 140 with test base is the only sensible arrangement.
A test base has also been described as indispensable in the majority position, stated flatly: the compound would not be held without testosterone alongside it, and exposure to SARMs without a base is treated as an error needing explanation. The adverse effects attributed to the compound are said to follow from suppression, so the case for a base runs from that suppression to its replacement, and that single inference carries the whole argument.
The minority position rests on two different grounds in accounts outside the published studies: endogenous production is described as recovering better after the compound alone than after the compound with testosterone alongside it, and a base has a cost of its own, since testosterone must eventually be withdrawn as well, so one recovery problem becomes two.
Low libido, low energy and mood described without a base
Low libido
Low energy
Mood swings
Appetite changes
A persistent sense of suppression
Low libido continuing after exposure to SARMs has ended
Those effects are described outside the trials. The three at the head of the list set in where no base is held, with their onset placed consistently within the opening fortnight to the first month rather than later; appetite changes sometimes accompany them; the two at the foot appear in only a few accounts; and these descriptions, rather than any argument about lean body mass, are the reason most often given for holding testosterone alongside the compound.
How do you tell if a side effect comes from RAD140 or from TRT?
Where RAD 140 and TRT overlap, telling whether an adverse effect comes from one or the other is generally held to be impossible by any dependable means, because the effects described for each agent are the same, for the RAD 140 side effects as for those of testosterone:
lowered HDL cholesterol
raised liver enzymes
acne
hair loss
changes in mood
Some dividing lines are commonly drawn from pharmacology rather than from direct comparison. Testolone is not converted to oestradiol, so oestrogen-related effects such as changes in breast tissue and fluid retention are usually attributed to the testosterone; by the same reasoning a raised haematocrit is widely understood as a typical effect of testosterone therapy, and drug-induced liver injury is the effect the case literature most often links to selective androgen receptor modulators.
Clinical attribution rests, in those accounts, on timing, on whether the effect fades when one agent is withdrawn, and on blood values read against a baseline, and all three give likelihoods rather than proof; the picture is clouded further because material sold as the compound is commonly found mislabelled or adulterated, so an adverse effect may not trace back to RAD140 at all.
The difficulty of telling the two agents apart has also been described as a disagreement, in which an adverse effect arising during concurrent exposure to both is attributed to the compound, to the testosterone or to coincidence, while a fourth reading doubts that the material contained RAD140 at all; an effect first attributed to the compound is commonly described later as having nothing to do with it, or as probably unrelated, withdrawal of one agent to see whether the effect resolves has been described, and so has the reverse sequence, testosterone prescribed after exposure to the compound, so that the two overlap in time and neither can be isolated.
Hair, breast tissue, blood pressure and other complaints described in discussions
Outside the published trials, hair loss is described more often than any other complaint attached to the SARM RAD140, and the description is almost always followed by a comparative question on SARMs and hair loss: which compounds of the class are least likely to cause hair shedding, and whether a milder agent exists with the same effect on lean body mass, permanence being the concern behind it.
Among the effects described outside the trials, the complaints named run as follows:
hair loss
hair thinning and shedding, described as its visible form
swelling of breast tissue, appearing less often than hair loss
lowered oestrogen rather than raised, described beyond the trial data in one account of RAD140 added to prescribed testosterone
raised blood pressure, a concern put as a question about which SARM lacks that effect
appetite change and altered libido, which in descriptions beyond the trials occasionally appear together, as a pair rather than as separate complaints
What RAD140 dose and cycle length are used on TRT?
Amounts of RAD140 held alongside replacement testosterone are commonly described as far below those administered in the one human study, over a period of weeks rather than months, with the testosterone kept at or a little above its replacement level, and the figures rest on description alone, because no trial administered RAD 140 and TRT together.
What the published record supplies instead is a ceiling from oncology. The compound was escalated through three dose levels in women with metastatic breast cancer, 100 mg a day was established as the highest level carried without unacceptable toxicity, and 150 mg exceeded that ceiling; those were cancer doses selected by escalation, marking the top of human exposure rather than any comparable amount, and the amounts described elsewhere as a RAD140 dose sit far below them.
Dose cohorts in the RAD140 trial
Trial arm (once daily)
Patients
Outcome of escalation
50 mg
n = 6
Below the maximum tolerated dose
100 mg
n = 13
Maximum tolerated dose; 1 partial response in a patient with an ESR1 mutation
150 mg
n = 3
Exceeded the maximum tolerated dose
The elimination half-life is the only published basis for any statement about dosing interval, since it was the reason the investigators chose once-daily administration in that study; disease progression and toxicity governed duration there rather than a fixed schedule, so the trial fixes no length of exposure.
Does being on TRT cover RAD140 suppression, so no PCT is needed?
Testosterone replacement therapy is generally held to cover the suppression itself while replacement continues, since the hormone the axis would otherwise supply is already being given, but not to remove the recovery problem, which moves instead to whenever replacement stops; on that reading, the recorded evidence bears on the second half of the question rather than the first.
In the published case report the hypogonadotropic hypogonadism normalised fully once the products were stopped, whereas a narrative review of men after anabolic-androgenic steroid use finds recovery of the hypothalamic-pituitary-gonadal axis variable and no standardised treatment established for anabolic steroid-induced hypogonadism, the prolonged suppression that follows such exposure. Any account of PCT for RAD 140 has to rest on that record for this compound specifically.
Clinical studies consistently show improvements in hormonal parameters across different types of study participants, although symptomatic recovery varies and concerns remain regarding adverse metabolic and long-term efficacy.
The review also describes how recovery is pursued in practice after such exposure, through post-cycle therapy, treatment aimed at restoring endogenous production once exposure has ended. It records that therapy as frequently undertaken without medical supervision, using clomiphene citrate, human chorionic gonadotropin (hCG, a hormone that stimulates the testes directly) or aromatase inhibitors, drugs that block conversion of androgens to oestrogens, clomiphene the most common; hormonal values improve consistently across study types in that record, symptomatic recovery varies, and monitoring is itself a limitation, immunoassays having limited specificity where mass spectrometry offers greater reliability for assessing hormonal recovery and for detecting residual steroid metabolites. The subject of the review is anabolic-androgenic steroids, not SARMs.
Coming off testosterone after RAD140, as discussions describe it
A base brings a recovery problem of its own among the effects described outside the trials, because testosterone must later be withdrawn and endogenous production then has to recover from both agents rather than one, so whether replacement testosterone, once begun, must continue permanently stands as an open question.
Two further questions recur alongside that one in those accounts: how recovery after SARMs differs from recovery after testosterone, and how suppression can occur at all when a base was held in place throughout.
Clomiphene and enclomiphene in research on hormone recovery
Clomiphene citrate is the off-label medication most commonly used in anabolic steroid-induced hypogonadism, and the review that records that fact also sets out why its efficacy, safety and optimal monitoring remain poorly defined. The drug acts through a single mechanism, antagonism at oestrogen receptors, which weakens the negative feedback oestrogen exerts on the hypothalamic-pituitary axis, so that gonadotropin secretion rises, stimulating endogenous testosterone production and preserving spermatogenesis; the mechanism is indirect, so it depends on an axis still able to respond, and it is there that the review places its doubts about long-term efficacy and adverse metabolic effects, while recording hormonal parameters improving consistently across different types of study participants and symptomatic recovery showing no such consistency.
[Figure 1. How clomiphene is held to raise testosterone. Clomiphene blocks oestrogen receptors, weakening the feedback that restrains the pituitary, so LH and FSH rise and the testes are stimulated. From a narrative review of men after anabolic steroid use; not studied after RAD140.]
Enclomiphene, one of the two isomers that make up clomiphene, appears in that review among emerging approaches, beside kisspeptin analogues and genotype-guided interventions, and none of these has yet been validated in men recovering from steroid exposure; the review’s population consists throughout of men after anabolic-androgenic steroid use, not men exposed to RAD140. Laboratories studying that isomer can buy enclomiphene UK from the shop for research purposes.
Can a SERM such as Nolvadex or enclomiphene, or 4-andro, act as a base instead of testosterone?
Outside the published trials, a SERM is described as an alternative base that keeps endogenous production running instead of replacing it, the examples named being enclomiphene during a SARM cycle and tamoxifen (Nolvadex, an oestrogen receptor antagonist in breast tissue), and the counter-argument is stated just as plainly: such an agent supplies no testosterone and so is not a base in the sense the term otherwise carries.
4-andro (a prohormone converted in the body to testosterone) has also been described as a base, though less often, usually applied topically as a cream and usually paired with enclomiphene as a substitute for injections; the same question is put about hCG and clomiphene, DHEA is cast as an oestrogen base rather than a testosterone one, and RAD140 is occasionally said to serve as its own base, a claim that other accounts dismiss outright.
Which blood tests should be checked, and how often?
The blood values that changed in the only human trial of RAD140 begin with the liver enzymes AST and ALT, raised in 59.1% and 45.5% of patients respectively, then total bilirubin, raised in 27.3%, and the hormone markers SHBG and PSA, each read at baseline and again during treatment. The liver rises were the most frequent finding of that study, so the transaminases AST and ALT carry the clearest claim on repeat measurement.
The SHBG fall and PSA rise served the investigators to confirm androgen receptor engagement, and those markers are the whole of what RAD 140 blood work can draw on from the trial record, for what they show and for what they do not.
The record for the SARM class adds a pattern the trial did not emphasise. LiverTox, the United States reference database on drug-induced liver injury, records selective androgen receptor modulators as a class associated with cholestatic liver injury, which slows bile flow rather than destroying liver cells, and bilirubin and alkaline phosphatase carry that pattern as much as the transaminases do, so a panel confined to AST and ALT would not show it.
The frequency of such testing is generally described as a baseline set of values before any exposure, repeat measurements while it continues and a further set once it ends, the sequence the trial itself followed; any closer spacing is a matter of clinical judgement rather than an established standard.
Why product contents matter more on testosterone
Product contents bear directly on the TRT question, because the undisclosed testosterone, oestradiol and growth hormone detected in all three supplements of the published case report were present without the patient’s knowledge. In a patient already receiving testosterone replacement therapy, hidden testosterone of that kind would add invisibly to the prescribed amount; the blood values would then be read as a response to the prescription, and any dose adjustment made on that reading would be mistaken.
Under-dosing causes the mirror problem. The Therapeutic Goods Administration (TGA), Australia’s medicines regulator, found on testing that unapproved SARM products were significantly under-dosed, so an effect attributed to RAD140 may come in fact from the accompanying testosterone, and on a replacement regimen that error is harder to catch than without one, because the prescribed hormone supplies a plausible cause for almost any change and an under-dosed product is credited with whatever the testosterone does.
[Figure 2. Undeclared testosterone in analysed RAD140 products. The laboratory analysis of three commercial products in one case report: banned agents alongside the named compound, undeclared testosterone, oestradiol and growth hormone, and a peak close to testosterone that could not be identified.]
Contents being the whole of this problem, laboratory work depends on batch and purity data, the analytical certificate issued for each lot. Researchers can buy RAD 140 UK with that certificate supplied, among the SARMs for sale in the catalogue for laboratory research.
Doubts about fake RAD140 in discussions
Beyond the trial data, an absent effect or an unexpected complaint is described as frequently answered with doubt about the material rather than about the compound: that the material was not RAD140, that the effect was a placebo response, or that a different substance was substituted after a first batch, and by the same reasoning capsule strengths that depart from the usual ones are read as a sign of that substitution.
Adulteration is described as a second suspicion in accounts outside the published studies, with prohormones, steroid precursors converted in the body to active androgens, named as the likely adulterant, and one objection cuts across all these suspicions: whether such material is legit RAD 140 cannot be known without analysis of its contents.
Limits of the evidence on RAD140 with testosterone
No published study among this article’s sources administered RAD140 together with testosterone, and the human evidence on vosilasarm amounts to one phase 1 oncology study in women with advanced breast cancer. The nearest approach to the combination is a published case report of a single patient exposed to mixed commercial products, in which the testosterone was undeclared and unquantified; beyond those two records, the liver evidence for the class is a LiverTox monograph rather than a study of this compound, the review of hormone recovery concerns men after anabolic-androgenic steroid use, and the TGA’s analysis of product contents covers products tested in Australia.
No published study among these sources has measured the following effects, known only from descriptions outside the trials:
low libido
low energy
mood changes
appetite changes
hair loss
lowered oestrogen
raised blood pressure
any added effect on lean body mass or fat mass relative to testosterone alone
Frequently asked questions
Would oral testosterone (Andriol) work as a base for RAD140?
Oral testosterone undecanoate (Andriol) is described, outside the trial record, as an unreliable way of holding a steady testosterone level, because its absorption depends on dietary fat and its blood concentration fluctuates through the day. The preparation is described as an oral alternative where an injectable route is set aside, with that limitation accepted rather than solved, and no study has examined testosterone undecanoate alongside RAD140.
Should the TRT dose change when RAD140 is added?
Any change to a prescribed testosterone dose is generally held to be a matter for the prescribing clinician rather than a fixed rule. RAD140 does not raise measured testosterone and lowers sex hormone-binding globulin, so total testosterone readings can fall during exposure, and laboratory values taken then are commonly described as harder to read against an earlier baseline.
How should estrogen be managed when RAD140 is added to TRT?
RAD140 is not aromatised to oestradiol, so when RAD 140 and TRT are combined, oestradiol is generally understood to be set by the testosterone rather than by the added compound. Oestradiol is commonly monitored in clinical practice during testosterone therapy, and in descriptions beyond the trials, falls in oestrogen during exposure are usually attributed to a lower testosterone level or to suppressed endogenous production.
Important information. This article summarises published research and case reports, and notes where effects are described outside the published trials. It is not medical advice, and Max Muscle Labs does not give dosing guidance or any information implying human use. Many of the compounds discussed here are not approved for human use by the MHRA, the FDA or any other regulator, and many are prohibited in sport by WADA. Products sold by Max Muscle Labs are supplied strictly for laboratory and analytical research use and are not for human or veterinary consumption.
Check what you remember
4 questions on this article; the right answer is marked.
Who was enrolled in the only human trial of RAD140?
Men already on testosterone replacement for low levels
Postmenopausal women with metastatic breast cancer ✓
Healthy young men in a muscle-building study
Older men with age-related muscle loss and frailty
The phase 1 trial enrolled 22 postmenopausal women with ER+/HER2- metastatic breast cancer, so it holds no readings from men on testosterone.
What was the most frequent adverse finding in the RAD140 trial?
Falls in HDL cholesterol and blood lipids
Raised haematocrit and blood pressure readings
Rises in the liver enzymes AST and ALT ✓
Growth of glandular breast tissue
AST was raised in 59.1% of patients and ALT in 45.5%, the most frequent events the trial recorded.
Besides the declared compounds, what did analysis of the case report's supplements find?
Undisclosed testosterone, oestradiol and growth hormone ✓
Far less RAD140 than the product labels declared
Ostarine and LGD-4033 sold in place of the labelled RAD140
Prohormones converted in the body to testosterone
All three supplements held testosterone, oestradiol and growth hormone that their labels did not declare.
What pattern of liver injury does LiverTox link to SARMs as a class?
Fatty liver from a build-up of fat in liver cells
Hepatocellular injury destroying liver cells
Liver tumours of the kind linked to older steroids
Cholestatic injury that slows the flow of bile ✓
LiverTox records SARMs as linked to cholestatic injury, so bilirubin and alkaline phosphatase matter as much as AST and ALT.
Specialty Registrar in Endocrinology and Diabetes; Clinical Research Fellow
Elizabeth Hyams is a specialty registrar in endocrinology and diabetes and a clinical research fellow in the Reproductive Endocrinology group at Imperial College London. Elizabeth specialises in endocrinology and the hypothalamic-pituitary-gonadal axis.
Reviewed by
Ailsa Gemmell· NHS Greater Glasgow and Clyde ·Last reviewed
Specialty Registrar in Gastroenterology
Ailsa Gemmell is a specialty registrar in gastroenterology at NHS Greater Glasgow and Clyde. Ailsa specialises in hepatology and liver safety.
RAD140 vs testosterone compared on potency, prostate sparing and suppression, from binding assays, rat studies and the one human trial in breast cancer.
RAD 140 vs LGD has never been compared in a trial: LGD-4033’s trial lowered testosterone and HDL, while RAD140’s raised liver enzymes in most participants.
Hurry while stocks last! Use code PAYDAY15 at checkout to get 15% off sitewide. Valid for
Join the WaitlistWe will inform you when the product is back in stock. Enter your email address below.
RAD 140 and TRT: the evidence on a testosterone base
By Elizabeth Hyams · Reviewed by Ailsa Gemmell
Published · 25 min read
RAD 140 and TRT at a glance
RAD 140 and TRT have never been measured in combination: no study has administered RAD140, a selective androgen receptor modulator (SARM) developed in oncology, with testosterone replacement therapy (TRT), testosterone prescribed to replace a low level. The only human trial, in women with breast cancer, recorded rises in liver enzymes, a risk that added testosterone does not cover.
Beyond that trial the published record on the combination is one case report, a single patient in whom products containing RAD-140 suppressed endogenous testosterone production until they were stopped. Outside the published trials, accounts of RAD 140 and libido describe that suppression as bringing low libido, low energy and mood swings where no base is held, and a testosterone base as replacing the lost production.
Two features of the compound frame the combination. RAD140 acts at the same site as testosterone rather than through a separate pathway, both binding the androgen receptor, a protein inside cells that responds to androgens; and the compound has been tested in humans only in a phase 1 trial (the earliest stage of clinical testing) in postmenopausal women with breast cancer, a population with no testicular output to suppress.
Nothing in the trial record describes the compound combined with a replacement dose of testosterone, and the RAD 140 science behind that record is a development history in oncology, not in hormone replacement.
Within those limits, this article sets out what the trial, the published case report and a review of hormone recovery hold on the combination, together with what is described outside the published studies; how either compound is administered, and the basics of RAD140 on its own, stay outside it.
What is a test base?
In descriptions beyond the trials, a test base is testosterone administered alongside a suppressive compound such as RAD 140, so that circulating testosterone is maintained while endogenous production falls; that fall is suppression, the decline in endogenous hormone output under an exogenous androgen, and RAD140 testosterone suppression of this kind is the reason these descriptions give for maintaining such a base.
Such a base has also been widely described, in those accounts, as already supplied by TRT at a prescribed replacement level, which is why the question of a base is put differently where testosterone is already prescribed (whether anything need change) than where it is not (what should be added). Other agents are sometimes described as a base too, among them a selective oestrogen receptor modulator (SERM), a drug whose action at the oestrogen receptor differs by tissue, and dehydroepiandrosterone (DHEA), an adrenal precursor steroid; the term itself belongs to these descriptions rather than to the medical literature, which recognises no such category.
What the RAD140 trial recorded on hormones
For a question about a testosterone base, the only human RAD 140 study has one defining feature: it enrolled nobody with testicular output. Its 22 participants were postmenopausal women with heavily pretreated metastatic breast cancer, 21 of them with androgen receptor-positive tumours, and it was built to find a tolerable dose in that disease, as a 3 + 3 dose escalation with an attached pharmacokinetic expansion cohort (small groups stepped up through rising doses until toxicity appears) at 50 mg (n = 6), 100 mg (n = 13) and 150 mg (n = 3), orally once daily, not to measure any hormonal axis.
The dose and the interval came out of that design. Toxicity appeared at the top level, so the maximum tolerated dose (the highest carried without unacceptable toxicity) was 100 mg a day, and the once-daily interval rested on the RAD 140 half life, an elimination half-life, the time a blood concentration takes to halve, of 44.7 hours.
On the endocrine side the trial read two surrogates of receptor engagement, and in women without testes both moved as a working androgen would: sex hormone-binding globulin (SHBG, the blood protein that binds testosterone) fell in 18 of 18 patients measured, and prostate-specific antigen (PSA), whose production rises on androgen receptor activation, rose. The two readings agreed with each other and with paired tumour biopsies taken before and during treatment, which is why the investigators treated receptor occupancy as demonstrated rather than inferred.
The risk that added testosterone does not cover is hepatic, since signs of RAD 140 liver toxicity dominated the trial’s safety record.
Does RAD140 shrink the prostate, and does that matter on TRT?
RAD140 has not been shown to shrink prostate tissue, and nothing in its only human trial points to such an effect: PSA rose in 16 of 20 patients in whom it was measured, and the authors read the rise as evidence of receptor engagement rather than of any action on the gland itself.
The patients were postmenopausal women, so prostate tissue was neither present nor measured and the PSA signal stands only as a pharmacodynamic marker. For TRT the limitation is specific: a rise in women cannot be carried over to men whose prostate tissue is already exposed to replacement testosterone, since the published record holds no readings from such men given RAD140, though the direction of the marker runs against the idea of a compound that lowers androgenic activity in the gland.
Hormone shutdown in a case report of products containing RAD140
Analytical chemistry, not the clinical course, is what makes the case report bear on a question about testosterone. The patient was a 40-year-old man with six months of exposure to three commercial supplements behind him when he presented with bilateral gynaecomastia (growth of glandular breast tissue in a male) and biochemical hypogonadotropic hypogonadism (low sex hormones that follow a reduced pituitary signal to the testes); in vitro analysis of the products detected RAD-140 alongside cardarine (a metabolic agent) and MK-677, a secretagogue that raises growth hormone, and the table below gives the whole inventory.
What the case report’s supplements contained
The declared contents were not the whole of what the products held. All three contained undisclosed testosterone, oestradiol and growth hormone, and steroid analysis by liquid chromatography mass spectrometry also detected an unidentified compound coeluting close to the testosterone peak. That coeluting peak is the detail that bears on this article: a substance that cannot be resolved from testosterone on a chromatogram would be indistinguishable from prescribed testosterone as well, and the analysis could put no quantity on either.
Once the products were withdrawn, every symptom resolved and the hypogonadotropic hypogonadism normalised. What the report records is reversibility, not a deliberate combination: the testosterone was undeclared, its amount unknown, several active compounds were present at once, and the whole observation rests on one patient (n = 1).
Does RAD140 with testosterone affect fertility?
RAD140 combined with testosterone is generally held to suppress male fertility, because each agent on its own is understood to lower the pituitary hormones that drive sperm production: exogenous testosterone reduces luteinising hormone and follicle-stimulating hormone, a fall that lowers intratesticular testosterone concentrations and can reduce or halt spermatogenesis, and SARMs suppress the same two hormones in a dose-dependent way, so the combination is expected to add to that suppression rather than offset it.
Once that androgen exposure ends, recovery of spermatogenesis is generally described as possible but slow, and as variable between individuals; for RAD140 itself, data on fertility in humans remain very limited, and none of the studies among this article’s sources measured semen parameters.
Why do people add RAD140 to TRT or a testosterone base?
Pairing RAD 140 and TRT, or a testosterone base, is described, outside the trial record, as resting most commonly on suppression, with the base said to replace the endogenous production the compound lowers, and the accounts that describe a RAD 140 and testosterone stack give the reasons below, from a settled argument to a question asked with no reason at all:
The evidence behind a RAD 140 stack covers less of such arrangements than those accounts assume.
RAD140 as a replacement for TRT in discussions
Beyond the trial data, RAD140 is sometimes described as a substitute for testosterone replacement therapy, and the claim meets an immediate objection, since a compound that suppresses endogenous testosterone cannot stand in for testosterone, and on that ground the substitution is sometimes described as a failure.
Variants of the substitution claim stand around the edges of that position in the same accounts, and the claims described run as follows:
All of these variants remain claims in those accounts rather than findings of the research record.
Does RAD140 on TRT give more than testosterone alone or a higher test dose?
Accounts outside the published studies describe RAD140 added to testosterone replacement therapy as contributing less than a higher dose of testosterone, most of them holding that more testosterone would produce an equal or greater effect with fewer unknowns, and the comparison is often put as a direct question: why the compound rather than testosterone, and why not raise the testosterone dose instead of introducing a second agent.
RAD140 added to prescribed testosterone has also been described as producing an effect that testosterone alone had not produced, a less frequent and occasionally emphatic account that most often names a reduction in fat mass or an increase in muscle strength, while elsewhere any such change is credited wholly to the prescribed testosterone and not at all to the compound, the same comparison made from the other end.
In those accounts each agent can at least be compared directly with placebo within its own evidence, and set out that way RAD 140 vs testosterone becomes a comparison of the underlying suppression and marker data.
Is a test base needed with RAD140?
A test base is most often held, among the effects described outside the trials, to be needed with RAD140 because the compound is highly suppressive, while a smaller set of accounts holds that it is not necessary; the disagreement comes back as one of the questions put most often, and in almost identical words, whether RAD 140 with test base is the only sensible arrangement.
A test base has also been described as indispensable in the majority position, stated flatly: the compound would not be held without testosterone alongside it, and exposure to SARMs without a base is treated as an error needing explanation. The adverse effects attributed to the compound are said to follow from suppression, so the case for a base runs from that suppression to its replacement, and that single inference carries the whole argument.
The minority position rests on two different grounds in accounts outside the published studies: endogenous production is described as recovering better after the compound alone than after the compound with testosterone alongside it, and a base has a cost of its own, since testosterone must eventually be withdrawn as well, so one recovery problem becomes two.
Low libido, low energy and mood described without a base
Those effects are described outside the trials. The three at the head of the list set in where no base is held, with their onset placed consistently within the opening fortnight to the first month rather than later; appetite changes sometimes accompany them; the two at the foot appear in only a few accounts; and these descriptions, rather than any argument about lean body mass, are the reason most often given for holding testosterone alongside the compound.
How do you tell if a side effect comes from RAD140 or from TRT?
Where RAD 140 and TRT overlap, telling whether an adverse effect comes from one or the other is generally held to be impossible by any dependable means, because the effects described for each agent are the same, for the RAD 140 side effects as for those of testosterone:
Some dividing lines are commonly drawn from pharmacology rather than from direct comparison. Testolone is not converted to oestradiol, so oestrogen-related effects such as changes in breast tissue and fluid retention are usually attributed to the testosterone; by the same reasoning a raised haematocrit is widely understood as a typical effect of testosterone therapy, and drug-induced liver injury is the effect the case literature most often links to selective androgen receptor modulators.
Clinical attribution rests, in those accounts, on timing, on whether the effect fades when one agent is withdrawn, and on blood values read against a baseline, and all three give likelihoods rather than proof; the picture is clouded further because material sold as the compound is commonly found mislabelled or adulterated, so an adverse effect may not trace back to RAD140 at all.
The difficulty of telling the two agents apart has also been described as a disagreement, in which an adverse effect arising during concurrent exposure to both is attributed to the compound, to the testosterone or to coincidence, while a fourth reading doubts that the material contained RAD140 at all; an effect first attributed to the compound is commonly described later as having nothing to do with it, or as probably unrelated, withdrawal of one agent to see whether the effect resolves has been described, and so has the reverse sequence, testosterone prescribed after exposure to the compound, so that the two overlap in time and neither can be isolated.
Hair, breast tissue, blood pressure and other complaints described in discussions
Outside the published trials, hair loss is described more often than any other complaint attached to the SARM RAD140, and the description is almost always followed by a comparative question on SARMs and hair loss: which compounds of the class are least likely to cause hair shedding, and whether a milder agent exists with the same effect on lean body mass, permanence being the concern behind it.
Among the effects described outside the trials, the complaints named run as follows:
What RAD140 dose and cycle length are used on TRT?
Amounts of RAD140 held alongside replacement testosterone are commonly described as far below those administered in the one human study, over a period of weeks rather than months, with the testosterone kept at or a little above its replacement level, and the figures rest on description alone, because no trial administered RAD 140 and TRT together.
What the published record supplies instead is a ceiling from oncology. The compound was escalated through three dose levels in women with metastatic breast cancer, 100 mg a day was established as the highest level carried without unacceptable toxicity, and 150 mg exceeded that ceiling; those were cancer doses selected by escalation, marking the top of human exposure rather than any comparable amount, and the amounts described elsewhere as a RAD140 dose sit far below them.
Dose cohorts in the RAD140 trial
The elimination half-life is the only published basis for any statement about dosing interval, since it was the reason the investigators chose once-daily administration in that study; disease progression and toxicity governed duration there rather than a fixed schedule, so the trial fixes no length of exposure.
Does being on TRT cover RAD140 suppression, so no PCT is needed?
Testosterone replacement therapy is generally held to cover the suppression itself while replacement continues, since the hormone the axis would otherwise supply is already being given, but not to remove the recovery problem, which moves instead to whenever replacement stops; on that reading, the recorded evidence bears on the second half of the question rather than the first.
In the published case report the hypogonadotropic hypogonadism normalised fully once the products were stopped, whereas a narrative review of men after anabolic-androgenic steroid use finds recovery of the hypothalamic-pituitary-gonadal axis variable and no standardised treatment established for anabolic steroid-induced hypogonadism, the prolonged suppression that follows such exposure. Any account of PCT for RAD 140 has to rest on that record for this compound specifically.
The review also describes how recovery is pursued in practice after such exposure, through post-cycle therapy, treatment aimed at restoring endogenous production once exposure has ended. It records that therapy as frequently undertaken without medical supervision, using clomiphene citrate, human chorionic gonadotropin (hCG, a hormone that stimulates the testes directly) or aromatase inhibitors, drugs that block conversion of androgens to oestrogens, clomiphene the most common; hormonal values improve consistently across study types in that record, symptomatic recovery varies, and monitoring is itself a limitation, immunoassays having limited specificity where mass spectrometry offers greater reliability for assessing hormonal recovery and for detecting residual steroid metabolites. The subject of the review is anabolic-androgenic steroids, not SARMs.
Coming off testosterone after RAD140, as discussions describe it
A base brings a recovery problem of its own among the effects described outside the trials, because testosterone must later be withdrawn and endogenous production then has to recover from both agents rather than one, so whether replacement testosterone, once begun, must continue permanently stands as an open question.
Two further questions recur alongside that one in those accounts: how recovery after SARMs differs from recovery after testosterone, and how suppression can occur at all when a base was held in place throughout.
Clomiphene and enclomiphene in research on hormone recovery
Clomiphene citrate is the off-label medication most commonly used in anabolic steroid-induced hypogonadism, and the review that records that fact also sets out why its efficacy, safety and optimal monitoring remain poorly defined. The drug acts through a single mechanism, antagonism at oestrogen receptors, which weakens the negative feedback oestrogen exerts on the hypothalamic-pituitary axis, so that gonadotropin secretion rises, stimulating endogenous testosterone production and preserving spermatogenesis; the mechanism is indirect, so it depends on an axis still able to respond, and it is there that the review places its doubts about long-term efficacy and adverse metabolic effects, while recording hormonal parameters improving consistently across different types of study participants and symptomatic recovery showing no such consistency.
Enclomiphene, one of the two isomers that make up clomiphene, appears in that review among emerging approaches, beside kisspeptin analogues and genotype-guided interventions, and none of these has yet been validated in men recovering from steroid exposure; the review’s population consists throughout of men after anabolic-androgenic steroid use, not men exposed to RAD140. Laboratories studying that isomer can buy enclomiphene UK from the shop for research purposes.
Can a SERM such as Nolvadex or enclomiphene, or 4-andro, act as a base instead of testosterone?
Outside the published trials, a SERM is described as an alternative base that keeps endogenous production running instead of replacing it, the examples named being enclomiphene during a SARM cycle and tamoxifen (Nolvadex, an oestrogen receptor antagonist in breast tissue), and the counter-argument is stated just as plainly: such an agent supplies no testosterone and so is not a base in the sense the term otherwise carries.
4-andro (a prohormone converted in the body to testosterone) has also been described as a base, though less often, usually applied topically as a cream and usually paired with enclomiphene as a substitute for injections; the same question is put about hCG and clomiphene, DHEA is cast as an oestrogen base rather than a testosterone one, and RAD140 is occasionally said to serve as its own base, a claim that other accounts dismiss outright.
Which blood tests should be checked, and how often?
The blood values that changed in the only human trial of RAD140 begin with the liver enzymes AST and ALT, raised in 59.1% and 45.5% of patients respectively, then total bilirubin, raised in 27.3%, and the hormone markers SHBG and PSA, each read at baseline and again during treatment. The liver rises were the most frequent finding of that study, so the transaminases AST and ALT carry the clearest claim on repeat measurement.
The SHBG fall and PSA rise served the investigators to confirm androgen receptor engagement, and those markers are the whole of what RAD 140 blood work can draw on from the trial record, for what they show and for what they do not.
The record for the SARM class adds a pattern the trial did not emphasise. LiverTox, the United States reference database on drug-induced liver injury, records selective androgen receptor modulators as a class associated with cholestatic liver injury, which slows bile flow rather than destroying liver cells, and bilirubin and alkaline phosphatase carry that pattern as much as the transaminases do, so a panel confined to AST and ALT would not show it.
The frequency of such testing is generally described as a baseline set of values before any exposure, repeat measurements while it continues and a further set once it ends, the sequence the trial itself followed; any closer spacing is a matter of clinical judgement rather than an established standard.
Why product contents matter more on testosterone
Product contents bear directly on the TRT question, because the undisclosed testosterone, oestradiol and growth hormone detected in all three supplements of the published case report were present without the patient’s knowledge. In a patient already receiving testosterone replacement therapy, hidden testosterone of that kind would add invisibly to the prescribed amount; the blood values would then be read as a response to the prescription, and any dose adjustment made on that reading would be mistaken.
Under-dosing causes the mirror problem. The Therapeutic Goods Administration (TGA), Australia’s medicines regulator, found on testing that unapproved SARM products were significantly under-dosed, so an effect attributed to RAD140 may come in fact from the accompanying testosterone, and on a replacement regimen that error is harder to catch than without one, because the prescribed hormone supplies a plausible cause for almost any change and an under-dosed product is credited with whatever the testosterone does.
Contents being the whole of this problem, laboratory work depends on batch and purity data, the analytical certificate issued for each lot. Researchers can buy RAD 140 UK with that certificate supplied, among the SARMs for sale in the catalogue for laboratory research.
Doubts about fake RAD140 in discussions
Beyond the trial data, an absent effect or an unexpected complaint is described as frequently answered with doubt about the material rather than about the compound: that the material was not RAD140, that the effect was a placebo response, or that a different substance was substituted after a first batch, and by the same reasoning capsule strengths that depart from the usual ones are read as a sign of that substitution.
Adulteration is described as a second suspicion in accounts outside the published studies, with prohormones, steroid precursors converted in the body to active androgens, named as the likely adulterant, and one objection cuts across all these suspicions: whether such material is legit RAD 140 cannot be known without analysis of its contents.
Limits of the evidence on RAD140 with testosterone
No published study among this article’s sources administered RAD140 together with testosterone, and the human evidence on vosilasarm amounts to one phase 1 oncology study in women with advanced breast cancer. The nearest approach to the combination is a published case report of a single patient exposed to mixed commercial products, in which the testosterone was undeclared and unquantified; beyond those two records, the liver evidence for the class is a LiverTox monograph rather than a study of this compound, the review of hormone recovery concerns men after anabolic-androgenic steroid use, and the TGA’s analysis of product contents covers products tested in Australia.
No published study among these sources has measured the following effects, known only from descriptions outside the trials:
Frequently asked questions
Would oral testosterone (Andriol) work as a base for RAD140?
Oral testosterone undecanoate (Andriol) is described, outside the trial record, as an unreliable way of holding a steady testosterone level, because its absorption depends on dietary fat and its blood concentration fluctuates through the day. The preparation is described as an oral alternative where an injectable route is set aside, with that limitation accepted rather than solved, and no study has examined testosterone undecanoate alongside RAD140.
Should the TRT dose change when RAD140 is added?
Any change to a prescribed testosterone dose is generally held to be a matter for the prescribing clinician rather than a fixed rule. RAD140 does not raise measured testosterone and lowers sex hormone-binding globulin, so total testosterone readings can fall during exposure, and laboratory values taken then are commonly described as harder to read against an earlier baseline.
How should estrogen be managed when RAD140 is added to TRT?
RAD140 is not aromatised to oestradiol, so when RAD 140 and TRT are combined, oestradiol is generally understood to be set by the testosterone rather than by the added compound. Oestradiol is commonly monitored in clinical practice during testosterone therapy, and in descriptions beyond the trials, falls in oestrogen during exposure are usually attributed to a lower testosterone level or to suppressed endogenous production.
Check what you remember
4 questions on this article; the right answer is marked.
The phase 1 trial enrolled 22 postmenopausal women with ER+/HER2- metastatic breast cancer, so it holds no readings from men on testosterone.
AST was raised in 59.1% of patients and ALT in 45.5%, the most frequent events the trial recorded.
All three supplements held testosterone, oestradiol and growth hormone that their labels did not declare.
LiverTox records SARMs as linked to cholestatic injury, so bilirubin and alkaline phosphatase matter as much as AST and ALT.
Elizabeth Hyams · Imperial College London
Specialty Registrar in Endocrinology and Diabetes; Clinical Research Fellow
Elizabeth Hyams is a specialty registrar in endocrinology and diabetes and a clinical research fellow in the Reproductive Endocrinology group at Imperial College London. Elizabeth specialises in endocrinology and the hypothalamic-pituitary-gonadal axis.
Ailsa Gemmell · NHS Greater Glasgow and Clyde · Last reviewed
Specialty Registrar in Gastroenterology
Ailsa Gemmell is a specialty registrar in gastroenterology at NHS Greater Glasgow and Clyde. Ailsa specialises in hepatology and liver safety.
Related Posts
Ostarine vs LGD: trial data, RAD140, MK-677 and anavar
Ostarine vs LGD has never been tested in one trial: separate placebo trials each recorded over 1 kg more lean mass, with lower testosterone and HDL.
Is RAD 140 a steroid? How it differs from Anavar and tren
Is RAD 140 a steroid: no, it is a nonsteroidal SARM that activates the androgen receptor without the four-ring skeleton of Anavar or trenbolone.
RAD140 vs testosterone: strength, suppression and TRT
RAD140 vs testosterone compared on potency, prostate sparing and suppression, from binding assays, rat studies and the one human trial in breast cancer.
RAD 140 vs LGD: trial data, ostarine, YK-11 and MK-677
RAD 140 vs LGD has never been compared in a trial: LGD-4033’s trial lowered testosterone and HDL, while RAD140’s raised liver enzymes in most participants.